Gadofosveset (EPIX/Schering)

Aamer Farooki; Vamsidhar Narra; J. Brown Brown

Gadofosveset (EPIX/Schering)

Aamer Farooki
, Vamsidhar Narra
, J. Brown Brown

Research output: Contribution to journal › Review article › peer-review

Abstract

EPIX Medical and Schering are developing gadofosveset, an albumin-binding gadolinium-based intravascular magnetic resonance imaging contrast agent, for the potential imaging of blood vessels and blood flow, particularly in patients with peripheral vascular disease (PVD). By February 2004, US approval of the agent was anticipated in October 2004, and in June 2004, Schering filed an MAA in the EU for PVD.

Original language	English
Pages (from-to)	967-976
Number of pages	10
Journal	Current Opinion in Investigational Drugs
Volume	5
Issue number	9
State	Published - Sep 2004

Cite this

@article{9d347ee8ce46400ca6503efb573907d0,

title = "Gadofosveset (EPIX/Schering)",

abstract = "EPIX Medical and Schering are developing gadofosveset, an albumin-binding gadolinium-based intravascular magnetic resonance imaging contrast agent, for the potential imaging of blood vessels and blood flow, particularly in patients with peripheral vascular disease (PVD). By February 2004, US approval of the agent was anticipated in October 2004, and in June 2004, Schering filed an MAA in the EU for PVD.",

author = "Aamer Farooki and Vamsidhar Narra and Brown, \{J. Brown\}",

year = "2004",

month = sep,

language = "English",

volume = "5",

pages = "967--976",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

number = "9",

}

TY - JOUR

T1 - Gadofosveset (EPIX/Schering)

AU - Farooki, Aamer

AU - Narra, Vamsidhar

AU - Brown, J. Brown

PY - 2004/9

Y1 - 2004/9

N2 - EPIX Medical and Schering are developing gadofosveset, an albumin-binding gadolinium-based intravascular magnetic resonance imaging contrast agent, for the potential imaging of blood vessels and blood flow, particularly in patients with peripheral vascular disease (PVD). By February 2004, US approval of the agent was anticipated in October 2004, and in June 2004, Schering filed an MAA in the EU for PVD.

AB - EPIX Medical and Schering are developing gadofosveset, an albumin-binding gadolinium-based intravascular magnetic resonance imaging contrast agent, for the potential imaging of blood vessels and blood flow, particularly in patients with peripheral vascular disease (PVD). By February 2004, US approval of the agent was anticipated in October 2004, and in June 2004, Schering filed an MAA in the EU for PVD.

UR - https://www.scopus.com/pages/publications/16644389388

M3 - Review article

C2 - 15503653

AN - SCOPUS:16644389388

SN - 1472-4472

VL - 5

SP - 967

EP - 976

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 9

ER -

Gadofosveset (EPIX/Schering)

Abstract

Other files and links

Fingerprint

Cite this